tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Dumont FJ et al. | A tacrolimus-related immunosuppressant with reduced toxicity. | 1998 | Transplantation | pmid:9448138 |
| Miyauchi T et al. | Effect of donor-specific splenocytes via portal vein and FK506 in rat small bowel transplantation. | 1998 | Transplantation | pmid:9448139 |
| Calmus Y et al. | Assessing renal function with daclizumab induction and delayed tacrolimus introduction in liver transplant recipients. | 2010 | Transplantation | pmid:20495510 |
| Ouyang J et al. | Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections. | 2005 | Transplantation | pmid:15912108 |
| Egli A et al. | Inhibition of polyomavirus BK-specific T-Cell responses by immunosuppressive drugs. | 2009 | Transplantation | pmid:19935369 |
| Boyer O et al. | Improvement of renal function in pediatric heart transplant recipients treated with low-dose calcineurin inhibitor and mycophenolate mofetil. | 2005 | Transplantation | pmid:15912111 |
| Villanueva G and Baldwin D | Rosiglitazone therapy of posttransplant diabetes mellitus. | 2005 | Transplantation | pmid:16340782 |
| Numakura K et al. | Clinical and genetic risk factors for posttransplant diabetes mellitus in adult renal transplant recipients treated with tacrolimus. | 2005 | Transplantation | pmid:16340785 |
| Khanna A et al. | Donor bone marrow potentiates the effect of tacrolimus on nonvascularized heart allograft survival: association with microchimerism and growth of donor dendritic cell progenitors from recipient bone marrow. | 1998 | Transplantation | pmid:9500620 |
| Shihab FS et al. | Donor preconditioning with a calcineurin inhibitor improves outcome in rat syngeneic kidney transplantation. | 2009 | Transplantation | pmid:19202436 |
| Furukawa H et al. | The effect of bile duct ligation and bile diversion on FK506 pharmacokinetics in dogs. | 1992 | Transplantation | pmid:1373531 |
| de Sandes-Freitas TV et al. | Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus. | 2015 | Transplantation | pmid:25929604 |
| Ciancio G et al. | Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. | 2002 | Transplantation | pmid:11965039 |
| Kaufman DB et al. | Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. | 1999 | Transplantation | pmid:10071032 |
| Khanna A et al. | Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. | 1999 | Transplantation | pmid:10071036 |
| van Rijen MM et al. | CD154 is expressed during treatment with calcineurin inhibitors after organ transplantation. | 2002 | Transplantation | pmid:12042657 |
| Couzi L et al. | Immunological monitoring of calcineurin inhibitors for predicting cytomegalovirus infection in kidney transplant recipients. | 2008 | Transplantation | pmid:18946343 |
| Horner BM et al. | Recipient damage after musculocutaneous transplant rejection. | 2008 | Transplantation | pmid:18946349 |
| Bäckman L et al. | FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. | 1994 | Transplantation | pmid:7509516 |
| Imado T et al. | Effect of FK506 on donor T-cell functions that are responsible for graft-versus-host disease and graft-versus-leukemia effect. | 2004 | Transplantation | pmid:14966413 |
| Higgins RM et al. | Acute rejection after renal transplantation is reduced by approximately 50% by prior therapeutic blood transfusions, even in tacrolimus-treated patients. | 2004 | Transplantation | pmid:14966430 |
| Abadja F et al. | Impact of mycophenolic acid and tacrolimus on Th17-related immune response. | 2011 | Transplantation | pmid:21818055 |
| Jain AB et al. | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. | 1998 | Transplantation | pmid:9846530 |
| Herzog D et al. | Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. | 2006 | Transplantation | pmid:16534467 |
| Mañez R et al. | Anomalous pattern of IgG antibody response to primary cytomegalovirus infection after solid organ retransplantation. | 1995 | Transplantation | pmid:7537400 |
| Fujii Y et al. | Effect of a novel immunosuppressive agent, FK506, on mitogen-induced inositol phospholipid degradation in rat thymocytes. | 1989 | Transplantation | pmid:2472025 |
| Hanto DW and Chudzinski R | What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? | 2009 | Transplantation | pmid:19155968 |
| Schena FP et al. | Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. | 2009 | Transplantation | pmid:19155978 |
| Muthukkumar S et al. | Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells. | 1995 | Transplantation | pmid:7544036 |
| Muraki T et al. | Antithrombotic effect of FK506 versus prothrombotic effect of cyclosporine in vivo. | 1995 | Transplantation | pmid:7544038 |
| Boots JM et al. | Early steroid withdrawal in renal transplantation with tacrolimus dual therapy: a pilot study. | 2002 | Transplantation | pmid:12499885 |
| Fridell JA et al. | Causes of mortality beyond 1 year after primary pediatric liver transplant under tacrolimus. | 2002 | Transplantation | pmid:12499888 |
| Pape E et al. | Management of Tacrolimus-Telaprevir Drug-Drug Interaction in a Liver Transplant Patient With Hepatitis C Virus: Practical Considerations. | 2015 | Transplantation | pmid:26308424 |
| Saad ER et al. | Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. | 2008 | Transplantation | pmid:18360267 |
| Stephen M et al. | Immunosuppressive activity, lymphocyte subset analysis, and acute toxicity of FK-506 in the rat. A comparative and combination study with cyclosporine. | 1989 | Transplantation | pmid:2463701 |
| Uchikoshi F et al. | Restoration of immune abnormalities in diabetic BB rats after pancreas transplantation. I. Macrochimerism of donor-graft-derived RT6+ T cells responsible for restoration of immune responsiveness and suppression of autoimmune reaction. | 1996 | Transplantation | pmid:8669109 |
| Bolley R et al. | Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John's wort. | 2002 | Transplantation | pmid:11923712 |
| Mendez R et al. | A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. | 2005 | Transplantation | pmid:16082323 |
| Oku M et al. | Hepatocyte growth factor sustains T regulatory cells and prolongs the survival of kidney allografts in major histocompatibility complex-inbred CLAWN-miniature swine. | 2012 | Transplantation | pmid:22158517 |
| Report from the 4th International Workshop on Clinical Pharmacology of HIV Therapy. Drug levels in PHAs who receive liver transplants. | 2003 Apr-May | TreatmentUpdate | pmid:17216847 | |
| Kunz J and Hall MN | Cyclosporin A, FK506 and rapamycin: more than just immunosuppression. | 1993 | Trends Biochem. Sci. | pmid:7694398 |
| Cardenas ME et al. | Signal-transduction cascades as targets for therapeutic intervention by natural products. | 1998 | Trends Biotechnol. | pmid:9807840 |
| Snyder SH et al. | Neural actions of immunophilin ligands. | 1998 | Trends Pharmacol. Sci. | pmid:9509898 |
| Liu J | FK506 and ciclosporin: molecular probes for studying intracellular signal transduction. | 1993 | Trends Pharmacol. Sci. | pmid:7692652 |
| Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
| Sommerer C et al. | Design and rationale of the ATHENA study--A 12-month, multicentre, prospective study evaluating the outcomes of a de novo everolimus-based regimen in combination with reduced cyclosporine or tacrolimus versus a standard regimen in kidney transplant patients: study protocol for a randomised controlled trial. | 2016 | Trials | pmid:26888217 |
| Nashan B et al. | Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. | 2015 | Trials | pmid:25873064 |
| Bajetta E et al. | Merkel cell carcinoma after liver transplantation: a case report. | 2007 May-Jun | Tumori | pmid:17679476 |
| Vennarecci G et al. | [Acute liver toxicity of antiretroviral therapy (HAART) after liver transplantation in a patient with HIV-HCV coinfection and associated hepatocarcinoma (HCC)]. | 2003 Jul-Aug | Tumori | pmid:12903579 |
| Tümgör G et al. | A case of uneventful ABO-incompatible liver transplantation from a deceased donor managed with routine immunosuppressive treatment. | 2014 | Turk J Gastroenterol | pmid:25599790 |